Is ibogaine taken orally or by injection?

Orally. Ibogaine is administered in capsule form — most commonly as ibogaine hydrochloride (HCl) — and swallowed. There is no intravenous ibogaine protocol at legitimate providers. Any provider offering ibogaine by injection is not operating within established safety practice. Root bark from Tabernanthe iboga can also be administered orally in traditional Bwiti ceremony, though the alkaloid concentration per gram is lower and the experience unfolds differently than HCl.

What is a flood dose of ibogaine?

A flood dose is the full therapeutic dose: 15–20 mg/kg of body weight, calculated individually by the attending physician. Before the flood dose, a test dose of 2–3 mg/kg is administered and observed for several hours to assess cardiac response and individual sensitivity. The flood dose is administered only after the test dose is confirmed safe. The distinction matters: a provider who skips the test dose or calculates the flood dose without a physician's involvement is not operating safely.

Who is present when ibogaine is administered?

A licensed physician must be on-site — not on call, not reachable by phone — throughout the full 12–24 hours of the active experience. A trained facilitator is also present continuously. The combination of cardiac monitoring equipment and a physician capable of acting on what it shows is the minimum medical infrastructure. Facilities that describe their medical support as 'available if needed' or 'on call nearby' do not meet this standard.

How long is ibogaine active after it is administered?

The acute experience lasts 12–24 hours. The active metabolite noribogaine, which accounts for much of ibogaine's anti-craving and mood-stabilising effects, remains pharmacologically active for several weeks to months after a single dose — this is the neuroplasticity window during which new habits and patterns are most accessible. The recovery phase after the acute experience typically takes 2–3 days before normal functioning resumes.

Can ibogaine be administered at home or without medical supervision?

No. The cardiac risk ibogaine carries — specifically QT interval prolongation and the potential for ventricular arrhythmia — requires continuous ECG monitoring and a physician who can respond in real time. Documented fatalities from ibogaine have occurred in the absence of cardiac monitoring, in people who were subsequently found to have undetected cardiac conditions. Administering ibogaine without these safeguards in place is not a calculated risk. It removes the mechanism by which the risk is managed.

What cardiac monitoring is used during ibogaine administration?

Continuous 12-lead ECG monitoring throughout the active period. Additionally: IV hydration (typically 1 litre), intravenous magnesium sulfate to support cardiac stability, continuous pulse oximetry, blood pressure monitoring at regular intervals, and temperature monitoring. Ibogaine prolongs the QT interval — the portion of the cardiac cycle most associated with potentially fatal arrhythmias — and this monitoring is how an otherwise undetectable problem is caught before it becomes a fatality.

What medical screening is required before ibogaine can be administered?

A 12-lead EKG is required — not optional, not waivable. Beyond that: a full blood panel covering liver enzymes, kidney function, and complete blood count; a cardiovascular assessment; a comprehensive review of all medications and supplements; and a full medical and psychiatric history. Ibogaine has absolute contraindications that can be identified only through screening. Any provider who offers a ceremony date before completing this screening is not operating safely.

Who cannot receive ibogaine, regardless of how much they want it?

Absolute contraindications: QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction; SSRIs or SNRIs without a completed supervised taper (serotonin syndrome risk is real and potentially fatal — this is not a preference, it is a medical disqualifier, and no case is an exception); methadone without a supervised transition protocol; active psychosis or schizophrenia spectrum disorder; severe liver or kidney disease; lithium and most antipsychotics; pregnancy. Someone in acute psychiatric crisis is also not an appropriate candidate regardless of how much they want access. The experience amplifies what is present, not what the person hopes to find.

How Is Ibogaine Administered? Methods, Dosing, and Medical Monitoring

Ibogaine is administered orally — in capsules of the hydrochloride salt, or in traditional Bwiti ceremony as prepared whole root bark. The dose is calculated by body weight: a test dose of 2–3 mg/kg first, followed by a flood dose that brings the total to 15–20 mg/kg. How is ibogaine administered safely? Under continuous cardiac monitoring by an on-site physician, with IV hydration running throughout. Providers who skip that monitoring are not cutting costs. They are removing the safeguard that keeps administration from becoming a fatality.

In short: Ibogaine is taken orally — in capsules of ibogaine HCl in clinical settings, or as whole root bark in Bwiti ceremony. The standard flood dose totals 15–20 mg/kg of body weight, preceded by a test dose of 2–3 mg/kg. An on-site physician monitors continuous cardiac function throughout the 12–24 hour active experience. This is not optional infrastructure.

Why Ibogaine Is Taken Orally

Ibogaine hydrochloride — ibogaine HCl — is the form used in most clinical and ceremonial settings outside Africa. It is administered in capsules or tablets. There is no standard injectable or IV protocol in use at legitimate providers.

In traditional Bwiti ceremony in Gabon, the medicine is prepared from the scraped root bark of Tabernanthe iboga — a form that contains ibogaine alongside more than 30 other alkaloids. For the pharmacological distinction between the whole plant and the isolated compound, the iboga vs ibogaine comparison covers what changes — and what does not — between the two preparations.

Oral administration matters for monitoring. Because ibogaine is absorbed gradually through the gastrointestinal tract, onset is typically 30–90 minutes after the first capsule. This gives the medical team time to observe early cardiac and physiological responses before the full dose is active. An IV delivery would produce a faster onset that is considerably harder to manage. The oral route is not a simpler option. It is the one that allows adequate response time if something requires intervention.

Dosing: Test Dose and Flood Dose

The flood dose — the therapeutic dose used for addiction, PTSD, and treatment-resistant depression — totals 15–20 mg/kg of body weight in most protocols. This is not a fixed number pulled from a chart. It is calculated for the specific individual, with body weight as the base calculation and the physician's assessment of cardiac function and full medical history shaping the final figure.

Before the flood dose is administered, a test dose of approximately 2–3 mg/kg is given first. This is not optional. The test dose serves two purposes: it allows observation of the cardiac response to ibogaine in the specific individual, and it begins the experience at a level where any adverse response can be identified before the therapeutic dose follows.

The test dose is why the EKG happens before ceremony, not during it. An uncorrected QT prolongation at flood dose can produce lethal ventricular arrhythmia. The full pre-ceremony screening — 12-lead EKG, blood panel covering liver function, kidney function, and CBC, cardiovascular assessment, and complete medication review — identifies this before it becomes relevant. The test dose is the second checkpoint. The EKG is the first. The full contraindications list covers what the screening is looking for in each category.

Medical Monitoring During the Session

After the flood dose is administered, an on-site physician remains present throughout the active period — 12–24 hours. The monitoring includes:

Continuous ECG telemetry for cardiac rhythm and QT interval throughout the active period
IV hydration — typically 1 litre of saline or lactated Ringer's — beginning before the flood dose
Magnesium sulfate supplementation, which reduces hypotension and cardiac risk during the experience and is standard in safety-conscious protocols
Blood oxygen saturation monitoring
Blood pressure monitoring
Temperature monitoring
Regular clinical assessment throughout the session

Any ibogaine provider who administers the medicine without a physician present throughout is not operating safely. This is not a nuanced position. Ibogaine prolongs the QT interval — a measure of cardiac electrical activity. In people with pre-existing QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction, the combination can produce fatal ventricular arrhythmia. Continuous monitoring identifies cardiac events in real time so they can be addressed. Removing that monitoring is not an operational efficiency. It is a decision to leave the person without the infrastructure to keep them safe if something goes wrong.

Providers charging significantly below market rate are almost always doing so by removing this infrastructure. A ceremony without a physician and continuous cardiac telemetry is not a lower-cost version of the same service. It is a different service — one that has killed people. The cardiac safety literature indexed through PubMed documents this consistently: the documented ibogaine deaths have almost uniformly involved either a cardiac contraindication not identified in advance, or the absence of adequate monitoring, or both.

The 12–24 Hours That Follow Administration

The full experience that unfolds after administration is covered in detail in the ibogaine experience post. The outline is this:

Ibogaine moves through three phases across the 12–24 hours. The first is visionary — biographical memory content, visual material, a quality most people describe as being shown rather than choosing to see. Ibogaine shows people what they have been avoiding, not what they came to find. This is not a recreational altered state. It does not accommodate avoidance.

The second phase is introspective — less visual, more cognitive, often physically demanding. Nausea is common. Movement is difficult. The experience is not comfortable, and comfort is not its purpose.

The third phase is residual stimulation — a quieter period of wakefulness that can persist for several hours after the main experience resolves. Sleep is typically not possible until this passes.

The recovery period runs 2–3 days post-ceremony. Noribogaine — ibogaine's primary active metabolite — remains in the body for weeks to months after the initial dose. This metabolite persistence is part of why ibogaine's effects on craving, mood, and neuroplasticity extend well past the ceremony itself. What ibogaine does to the brain during this window — the GDNF-driven neuroplastic changes visible on imaging — is what the integration period is designed to work with.

What a person does in that window — who supports them, what unaddressed conditions they return to, whether the environment and relationships that produced the original problem are actually changed — determines the long-term outcome more than the ceremony itself. The ceremony opens the window. The integration determines whether anything lasting comes from it.

Bwiti Ceremony vs. Clinical Administration

In the Bwiti tradition of Gabon and Cameroon, iboga root bark is administered as a whole-plant preparation rather than isolated ibogaine HCl. The pharmacological profile differs — more than 30 alkaloids, not one. The context differs: a Bwiti initiation is not a treatment session. It is an initiatory rite conducted within a communal ceremonial frame — music, fire, community, the presence of experienced practitioners — spanning the full duration and extending into the days that follow.

What does not differ is the cardiac risk. Tabernanthe iboga root bark contains the same alkaloids that cause QT prolongation. The ceremonial framing does not alter the pharmacology. Medical screening before Bwiti-lineage iboga ceremony is the same non-negotiable as before clinical ibogaine administration. Providers who offer traditional ceremony without cardiac screening are not honouring the tradition. They are using the ceremonial frame to avoid medical responsibility.

The Bwiti spiritual tradition post covers the Missoko lineage and the distinction between traditional initiation and the Western ceremonial model in more depth.

Who Should Not Receive Ibogaine

Not every person who wants ibogaine is an appropriate candidate for it. The screening process — EKG, blood panel, cardiovascular assessment, psychiatric history, and complete medication review — exists to identify the people for whom administration would be dangerous. It is not bureaucracy. It is how a physician finds a subclinical cardiac condition that produces no symptoms in daily life but can produce lethal arrhythmia during a flood dose.

The conversation that ends in “this is not the right path for you at this moment” is one of the most important things a legitimate provider does. People in crisis who have found a thread of hope do not receive a “no” easily. Saying it clearly, without cushioning, is an act of care — not rejection.

Absolute contraindications — these are not preferences:

QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction
Current SSRIs or SNRIs without a completed supervised taper — the risk of serotonin syndrome is real and potentially fatal, and there are no exceptions to this rule
Methadone — a specific transition protocol is required before ceremony is possible
Active psychosis or schizophrenia spectrum disorder
Severe liver or kidney disease
Lithium and certain other psychiatric medications
Pregnancy

Someone in acute psychiatric crisis is also not an appropriate candidate. The medicine amplifies what is present. Entering it in a state of acute instability does not produce stability.

Some contraindications are not permanent disqualifiers. SSRIs, for example, require a supervised taper — the timeline depends on the specific medication and the physician's assessment, but it is not an indefinite barrier. The full contraindications list covers which conditions require preparation versus which are absolute.

We tell people this directly, and without softening it. We would rather lose a potential participant than administer ibogaine to someone for whom it is genuinely dangerous.

Is This Right for You?

If you are researching how ibogaine is administered — building an accurate picture of what the process involves before deciding whether to pursue it — the next step is a direct conversation rather than more reading. The FAQ covers the most common questions about iboga and 5-MeO-DMT ceremony at Transcend. The ceremony page explains what each programme includes — what medical oversight is in place from screening through recovery, and what each day of a programme actually involves.

If you have read widely, understand what ibogaine ceremony requires, and believe your medical history makes you a plausible candidate, apply through the intake form. Every application receives a direct response within 2–3 business days. If your medical history includes anything on the contraindications list — a cardiac finding, a current medication, a prior psychiatric episode — say so. The intake conversation is designed to determine whether and how ceremony is possible, not to filter for the simplest cases.

Sources: Stanford / Nature Medicine (2023) · PubMed — ibogaine cardiac safety research · Global Ibogaine Therapy Alliance — safety standards